{"id":"W2754327139","doi":"10.1016/s0140-6736(17)32440-6","title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1704,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Janssen Biotech; National Cancer Institute; Stand Up To Cancer; EMD Serono; Genentech; ImmunoGen; Ajinomoto; Clovis Oncology; Amgen; American Association for Cancer Research; National Ovarian Cancer Coalition; Regeneron Pharmaceuticals; University College London; Cancer Research UK; Array BioPharma; Memorial Sloan-Kettering Cancer Center; Ajinomoto Pharmaceuticals; Roche; AbbVie; Merck; Ovarian Cancer Research Fund; AstraZeneca; OncoMed Pharmaceutical; Ovarian Cancer Research Fund Alliance; U.S. Department of Defense","keywords":"Medicine; Placebo; Oncology; Internal medicine; Ovarian carcinoma; Double blind; Ovarian cancer; Surgery; Cancer; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002213744,0.001521494,0.004024395,0.0004159884,0.0004644228,0.001112396,0.001168067,0.00232124,0.007533734],"category_scores_gemma":[0.001686543,0.0006683618,0.0025389,0.0005333351,0.001297955,0.001156834,0.0004201064,0.004116211,0.00141383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007199771,"about_ca_system_score_gemma":0.0009586539,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001320822,"about_ca_topic_score_gemma":0.002968155,"domain_scores_codex":[0.9993331,0.0003215375,0.00003930859,0.00012781,0.00004995495,0.000128305],"domain_scores_gemma":[0.9992168,0.0002393916,0.0001642844,0.00009010776,0.000042205,0.000247304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.979787,0.001722323,0.0002867952,0.0007232729,0.001120385,0.00003500428,0.00003360192,0.0001728431,0.001628078,0.00008447716,0.0009086413,0.01349762],"study_design_scores_gemma":[0.9730214,0.02466357,0.0009040945,0.00002862088,0.0003855557,0.00003089079,0.000009713796,0.0001612104,0.0001772778,0.00008987096,0.0005157768,0.00001201522],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.965858,0.01989803,0.001343279,0.001534424,0.00136152,0.003844523,0.002128333,0.0004783804,0.003553507],"genre_scores_gemma":[0.9802458,0.00586958,0.00176086,0.00201902,0.0006715829,0.003055948,0.001562067,0.00006278102,0.004752506],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007533734,"threshold_uncertainty_score":0.02520281,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.11880331611037,"score_gpt":0.3994762313502411,"score_spread":0.2806729152398711,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}